The p75NTR-induced Apoptotic Program Develops through a Ceramide-Caspase Pathway Negatively Regulated by Nitric Oxide*

Jean-Philippe LièvremontDagger §, Clara ScioratiDagger §, Elena Morandiparallel , Clara PaolucciDagger , Giuseppe Bunone**Dagger Dagger , Giuliano Della Valleparallel **, Jacopo MeldolesiDagger §§, and Emilio ClementiDagger ¶¶

From the Dagger  Department of Pharmacology and the Bruno Ceccarelli Center, University of Milan, the Consiglio Nazionale delle Ricerche Center of Molecular and Cellular Pharmacology, and DIBIT, Department of Neuroscience, San Raffaele Institute, 20132 Milan, Italy, the ** Department of Genetics and Microbiology, University of Pavia, 27100 Pavia, Italy, the Dagger Dagger  National Cancer Institute, 20129 Milan, Italy, the parallel  Department of Biology, University of Bologna, 40126 Bologna, Italy, and the ¶¶ Department of Pharmacology, School of Pharmacy, University of Calabria, 87036 Arcavacata di Rende, Italy

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

SK-N-BE neuroblastoma cell clones transfected with p75NTR and lacking Trk neurotrophin receptors, previously reported to undergo extensive spontaneous apoptosis and to be protected by nerve growth factor (NGF) (Bunone, G., Mariotti, A., Compagni, A., Morandi, E., and Della Valle, G. (1997) Oncogene 14, 1463-1470), are shown to exhibit (i) increased levels of the pro-apoptotic lipid metabolite ceramide and (ii) high activity of caspases, the proteases of the cell death cascade. In the p75NTR-expressing cells, these parameters were partially normalized by prolonged NGF treatment, which, in addition, decreased apoptosis, similar to caspase blockers. Conversely, exogenous ceramide increased caspase activity and apoptosis in both wild-type and p75NTR-expressing cells. A new p75NTR-expressing clone characterized by low spontaneous apoptosis exhibited high endogenous ceramide and low caspase levels. A marked difference between the apoptotic and resistant clones concerned the very low and high activities of nitric-oxide (NO) synthase, respectively. Protection from apoptosis by NO was confirmed by results with the NO donor S-nitrosoacetylpenicillamine and the NO-trapping agent hemoglobin. We conclude that the p75NTR receptor, while free of NGF, triggers a cascade leading to apoptosis; the cascade includes generation of ceramide and increased caspase activity; and the protective role of NO occurs at step(s) in between the latter events.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Apoptosis (programmed cell death) is now recognized to play fundamental roles in both the physiology and pathology of the brain. On the one hand, apoptosis is instrumental in the selection of neurons, working coordinately with neuroprotection (1, 2); on the other hand, it plays central roles in the development of specific diseases (3). Understanding of factors and mechanisms governing the apoptotic program of nerve cells represents therefore a key issue in modern biomedical sciences.

Among the neuronal pro-apoptotic factors, considerable attention is presently focused on NGF1 and its receptors. In classical studies, this neurotrophin has been shown to afford protection to various families of neurons, working through its high affinity receptor, TrkA. As far as the low affinity NGF receptor, p75NTR, initial studies suggested its role to be cooperative to TrkA (see, for example, Refs. 4 and 5). Recently, however, homologies have been noticed between the transduction domain of p75NTR and those of well known death receptors, i.e. the tumor necrosis factor-alpha receptor and CD95 (Fas, APO-1) (see Ref. 6). The latter are known to induce apoptosis via complex signal cascades including the generation of a lipid messenger, ceramide, and the proteolytic activation of cysteine proteases, the caspases (7, 8). At the moment, a pro-apoptotic role of p75NTR is supported by results in a variety of systems, including cultured cells as well as knockout and transgenic mice (9-11).

Compared with the other death receptors, p75NTR appears unique inasmuch as only in some cases, apoptosis was shown to develop following NGF binding, whereas in other cases, it occurred in the absence of the specific ligand (spontaneous apoptosis). The signaling events triggered in the first condition are beginning to be elucidated (11-14), whereas those of the second remain undefined. Whatever their nature, these events appear to operate within the cell under the control of various modulators, among which is the short-lived messenger NO (15). Based on results in a number of cell types, from macrophages to neurons, NO was initially suggested to work as a stimulator of apoptosis, whereas recently, it has been shown to play a protective role (16-19).

In this work, the signaling events responsible for p75NTR-induced apoptosis and their regulation by NO were investigated in a panel of transfected SK-N-BE human neuroblastoma clones, some of which had already been shown to undergo spontaneous apoptosis (20). The results demonstrate (i) that both ceramide and caspases play crucial roles in the death signaling cascade induced by p75NTR and (ii) that NO protects against the apoptotic program, working downstream of ceramide generation and upstream of the operative caspase cascade.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- The rabbit polyclonal antibody specific for human p75NTR (9651) was kindly provided by Dr. M. Chao. The rabbit polyclonal antibody specific for human caspase-1 (pan-ICE) and the mouse monoclonal antibody specific for human caspase-3 (clone 10C1.C9) were purchased from Oncogene Research Products (Cambridge, United Kingdom). The mouse monoclonal antibody specific for human Bcl-2 (clone 100) was from Ancell Corp. (Bayport, MN). The rabbit polyclonal antibody recognizing TrkA, TrkB, and TrkC (C14) was from Santa Cruz Biotechnology (Santa Cruz, CA). Culture sera and media were from Life Technology Inc. (Basel, Switzerland), Hygromycin, human recombinant NGF, and fluorescein isothiocyanate-annexin V were from Roche Molecular Biochemicals (Mannheim, Germany). C2-ceramide from BIOMOL (Bremen, Germany). The caspase fluorogenic substrate Ac-DEVD-AMC and inhibitors Ac-YVAD-CMK, DEVD-CHO, and Z-DEVD-FMK, SNAP, and L-NAME were from Calbiochem (San Diego, CA). Silica Gel 60 was from Merck (Milan, Italy). Bicinchoninic acid was from Pierce. L-[3H]Arginine and the enhanced chemiluminescence kit were from Amersham International (Buckinghamshire, United Kingdom). Hemoglobin, 8-Br-cGMP, propidium iodide, Nonidet P-40, and the remaining chemicals were from Sigma (Milan).

Clone Generation and Cell Culture-- The various p75NTR-expressing clones were developed as described (20). In brief, after transfection with a pC4SLR vector containing the coding sequence of the human p75NTR gene and the hygromycin resistance gene, selection was carried out in a medium supplemented with 300 µg/ml hygromycin, and colonies were isolated 4 weeks after transfection. The level of p75NTR expression in the clones and its localization in the plasma membrane were established by Western blotting as well as by immunofluorescence. Compared with the classical model of neurotrophin action, i.e. PC12 cells, they were of the order of 280% in the BEp75B, BEp75H, and BEp75AR clones (see also Bunone et al. (20)), whereas the BEp75Hy- clone expressed ~16% of protein in comparison with overexpressing clones. The resistant BEp75AR clone was obtained from one of the clones overexpressing the transfected receptor by isolating a rapidly growing colony that exhibited no sign of spontaneous apoptosis from a preparation kept in the selection medium.

Growth of wild-type SK-N-BE and clone cells was carried out as described (20). Briefly, the cells were maintained at 37 °C in 100-mm Petri dishes and bathed in RPMI 1640 medium supplemented with 2 mM glutamine, 15% fetal calf serum, and 50 µg/ml gentamycin under a 5% CO2 atmosphere. Hygromycin-resistant clones, including the BEp75AR clone, were grown in complete medium supplemented with the antibiotic (150 µg/ml).

Apoptosis: Induction and Protection-- Apoptosis of both parental and p75NTR-overexpressing clone cells was induced by overnight administration of exogenous C2-ceramide (50 µM) at 37 °C. Inhibition of apoptosis was induced in p75NTR-overexpressing clone cells by preincubation with the caspase inhibitors Ac-YVAD-CMK, Z-DEVD-FMK and DEVD-CHO (100 µM) for 24 or 48 h at 37 °C. NGF protection against p75NTR-induced apoptosis was studied by preincubating the p75NTR-overexpressing clone cells for 24 or 48 h with NGF (6 nM). To study the role of NO, the wild-type SK-N-BE cells were preincubated either with the NO donor SNAP (50, 100, and 300 µM) in the presence or absence of the NO scavenger hemoglobin (100 µM) or with the membrane-permeable cGMP analogue 8-Br-cGMP (500 µM) for 15 min at 37 °C before the overnight C2-ceramide treatment. The cells of the p75NTR-overexpressing clones that undergo spontaneous apoptosis were incubated for a total of 48 h in the presence of SNAP (300 µM), with changes of the medium occurring every 12 h.

Apoptosis Detection-- Apoptotic cells were identified by flow cytometry following two different protocols (21, 22). The first is based on the identification of a typical sub-G1 peak in single parameter DNA histograms. DNA was stained in unfixed cells incubated for 60 min at 37 °C in sodium citrate (0.1%), propidium iodide (50 mg/ml), RNase A (100 µg/ml), and Nonidet P-40 (0.01%). In the second method, useful for evaluating the fraction of cells undergoing apoptosis, phosphatidylserine exposure was monitored by staining for 15 min at room temperature with fluorescein isothiocyanate-annexin V (0.5 µg/ml) in the presence of divalent cations. The loss of the ability to exclude vital dyes was assessed using propidium iodide in an isotonic buffer (10 µg/ml in PBS). Early apoptotic cells exclude the dye, but are stained with annexin V, whereas non-apoptotic cells are negative for both. Cells were then analyzed either for DNA content or for annexin V staining using a fluorescence-activated cell sorter (FACStar Plus, Becton Dickinson, Sunnyvale, CA). Quantification of apoptotic cells was also assessed by monitoring internucleosomal fragmentation of genomic DNA using an immunoassay kit based on the recognition of released nucleosomes by mouse monoclonal antibodies directed against DNA and histones (Cell Death Detection Elisa Plus kit, Roche Molecular Biochemicals).

Ceramide Measurements-- Ceramide levels were assayed as described (16). Samples of 1 × 106 cells were processed for lipid extraction; dried under nitrogen; resuspended in a mixture containing cardiolipin (5 mM), diethylenetriaminepentaacetic acid (1 mM), and octyl beta -glucopyranoside (7.5%); and labeled using the diacylglycerol kinase assay. Ceramide phosphate was isolated by thin-layer chromatography (Silica Gel 60) using CHCl3/CH3OH/CH3COOH (65:15:5, v/v/v) as solvent and quantified by densitometric analysis of the radioactive spots. Authentic ceramide 1-phosphate was identified by autoradiography at RF = 0.25.

Electrophoresis and Western Blot Analysis-- Wild-type SK-N-BE cells and clones stably transfected with p75NTR were cultured, harvested using a Pasteur pipette, washed in PBS, and lysed in cell lysis buffer (150 mM NaCl, 15 mM MgCl2, 1 mM EGTA, 50 mM Hepes-KOH, 10% glycerol, and 1% Triton X-100, pH 7.5) supplemented with a protease inhibitor mixture (0.2 mM phenylmethylsulfonyl fluoride, 2 mM benzamidine, and 1 µg/ml o-phenanthroline). After 30 min at 4 °C on a slowly rotating device, the cell lysates were centrifuged (for 3 min at 5000 rpm in an Eppendorf microcentrifuge), and the supernatants were assayed for protein content by the bicinchoninic acid procedure.

For electrophoresis and Western blot analyses, protein suspensions were solubilized (10:7 ratio) in SDS sample buffer (48 mM Tris-HCl, pH 6.8, 0.8 M sucrose, 4% SDS, 8% beta -mercaptoethanol, and 0.008% bromphenol blue) and heated on a boiling water bath for 5 min. The solubilized proteins were loaded and separated on Laemmli-type SDS-polyacrylamide gels run as described (23). Polyacrylamide concentrations were typically 4% in the stacking gel and either 7 or 15% in the running gel for Trk or p75NTR, Bcl-2, and caspase-1 and -3, respectively. The separated proteins were electrotransferred in a cold room onto a 0.2-mm pore nitrocellulose membrane at a constant 70 mA for 16 h using a buffer containing 25 mM Tris, 192 mM glycine, and 20% methanol, pH 8.3. After brief staining with 0.2% (w/v) Ponceau Red in 3% trichloroacetic acid to reveal the standard molecular mass markers, the blots were blocked with 5% (w/v) low-fat dried milk in PBS supplemented with 0.01% (v/v) Tween 20 (PBS/Tween) and then exposed for 1 h at room temperature to the primary antibody. Blots were washed in 2.5% (w/v) milk in PBS/Tween (5 × 10 min). Immunostaining was then developed by the enhanced chemiluminescence kit, and the relevant bands were revealed were quantitated using a Molecular Dynamics Imagequant apparatus.

Caspase Activity Measurements-- Samples of 1 × 106 cells were rinsed in cold PBS and lysed in a buffer containing 25 mM Hepes, pH 7.5, 5 mM EDTA, 1 mM EGTA, 5 mM MgCl2, 5 mM dithiothreitol, 1% CHAPS, 10 µg/ml each pepstatin and leupeptin, and 1 mM phenylmethylsulfonyl fluoride. The cell lysates were centrifuged (for 3 min at 5000 rpm in an Eppendorf microcentrifuge), and the supernatants were stored at -80 °C until used. Protein content was assayed by the bicinchoninic acid procedure.

Lysates (25 µg of protein) were incubated at 37 °C in a buffer containing 25 mM Hepes, pH 7.5, 10% sucrose, 0.1% CHAPS, and 1 mM dithiothreitol supplemented with Ac-DEVD-AMC (50 µM). The increase in fluorescence following the cleavage of the fluorogenic AMC moiety was monitored and then quantified in a Perkin-Elmer LS50 fluorometer (excitation, 380 nm; and emission, 460 nm). For quantitation, standard curves using increasing concentrations of AMC moiety were performed in parallel.

NO Synthase Activity Assay-- Neuronal NO synthase activity was quantified by measuring the conversion of L-[3H]arginine to L-[3H]citrulline (24). Cells (maintained for 48 h in medium without L-arginine) were harvested and washed with cold PBS, and the pellet was resuspended in homogenization buffer containing 20 mM Hepes, pH 7.2, supplemented with 320 mM sucrose, 1 mM dithiothreitol, 1 mM EDTA, and a mixture of protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 2 mM benzamidine, and 10 µg/ml o-phenanthroline). The samples were immediately processed by adding 25 µl of cell extract (300-400 µg of protein) to 90 µl of reaction buffer (25 mM Tris, pH 7.4, supplemented with 3 µM tetrahydrobiopterin, 1 µM FAD, 1 µM FMN, 100 nM calmodulin, 1 mM NADPH, and 50 µM unlabeled L-arginine) containing L-[3H]arginine (0.5 µCi/sample) in the presence of 10 µl of 6 mM CaCl2. The reaction was carried out for 10 min at 37 °C and then stopped by addition of 2 ml of 50 mM Hepes, pH 5.5, supplemented with 5 mM EDTA. The solution was then applied to Dowex 50-X8-400 columns converted to the basic form. [3H]Citrulline not retained by the ion-exchange resin was immediately eluted and quantified in a Beckman beta -counter after addition of scintillation mixture. Samples containing either L-NAME (500 µM) or EDTA (2 mM) were processed in parallel as controls.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

p75NTR Signaling and Cell Death in p75NTR-overexpressing Cell Clones-- Receptor-induced apoptosis develops through a series of intracellular events. In addition to (or concomitantly with) the establishment of the death-inducing signaling complex by the recruitment to the plasma membrane receptors of specific cytosolic proteins (see Ref. 7), activation of lipid-specific enzyme(s) occurs, with ensuing generation of metabolites that appear to play a role in the development of the program. In particular, this is the case of ceramide (25-27), a sphingosine metabolite known to induce apoptosis even when administered to the cells as a synthetic, membrane-permeable analogue. Fig. 1 demonstrates the sensitivity of SK-N-BE cells to one of these analogues, C2-ceramide. The compound was administered in a range of concentrations (1-50 µM) (Fig. 1B), including the range of the endogenous metabolite estimated in our cell clones under resting conditions (5-12 µM) (see also Fig. 2). At all concentrations tested, the lipid metabolite was found to be distinctly more efficacious in the clones stably transfected with p75NTR cDNA than in the wild-type parental neuroblastoma cells (Fig. 1, A and B). Such an increased effect occurred in at least rough proportion to receptor expression: moderate in the cells of the BEp75Hy- clone (Hy- clone) and much stronger in those of the BEp75B clone (B clone), where expression is ~7-fold higher.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Spontaneous and ceramide-induced apoptosis in wild-type SK-N-BE cells and clones expressing different levels of the p75NTR receptor. A, apoptosis in wild-type cells (panel a) and two transfected clones with different levels of p75NTR expression (low levels in clone Hy- (panel b) and high levels in clone B (panel c)) is shown before (insets) and after overnight exposure to exogenous ceramide (50 µM). Apoptotic cells were revealed by FACS analysis. The results shown are representative of three to five experiments. In this and the following figures showing FACS analyses, the apoptotic cell peak is indicated by an arrowhead. B, concentration dependence of apoptosis induced in the indicated SK-N-BE cells by exogenous ceramide, administered as described for A. The arbitrary units on the ordinate refer to absorbance measured at 405 nm. wt, wild-type.

Subsequent experiments were carried out to investigate whether the role of ceramide is only pharmacological or is connected with the regulation of p75NTR-induced apoptosis. Fig. 2A suggests that this may indeed be the case. In fact, compared with wild-type cells, the resting levels of endogenous ceramide were higher in the p75NTR-expressing clones: 50% in the Hy- clone and >100% in the B clone and in the other p75NTR-overexpressing clone employed, BEp75H (H clone). Parallel to the results with endogenous ceramide were those with the cysteine proteases known to participate in the apoptotic operative cascade, i.e. the caspases (7, 8). The activity of the latter enzymes, already conspicuous compared with wild-type cells in the low expression clone, Hy-, reached values 50-85-fold higher in the overexpressing clones, B and H (Fig. 2B). Likewise, DNA laddering (a classical sign of apoptosis) was high (~10-fold of the wild-type value) in clone B, and this value was significantly decreased when cells were pretreated with membrane-permeable caspase inhibitors (Ac-YVAD-CMK, Z-DEVD-FMK, and DEVD-CHO (100 µM), administered either alone or in combination) (Table I and data not shown). In contrast, these peptides had no effect on the cell endogenous ceramide levels (Fig. 2A).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   Endogenous ceramide levels (A) and caspase activity (B) in wild-type SK-N-BE neuroblastoma cells and in various clones expressing different levels of the p75NTR receptor. A, the levels of endogenous ceramide were assayed in the wild-type cells and in three transfected clones in the absence (stippled bars) and presence (black bars) of the caspase inhibitors Ac-YVAD-CMK and Z-DEVD-FMK (100 and 50 µM) as described under "Experimental Procedures." The results shown (means ± S.D.) are representative of three consistent experiments. B, total cell lysates of the wild-type cells and of various p75NTR-transfected SK-N-BE clones were incubated at 37 °C with a 50 µM concentration of the fluorogenic substrate Ac-DEVD-AMC. The fluorescence increase following the cleavage of the AMC residue was monitored for 10 min at 37 °C. Data shown (means ± S.D.) are from the results of five experiments.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of caspase inhibitors and NGF treatment on apoptosis of clone B cells
Clone B cells were incubated in culture medium supplemented either with caspase inhibitors (Ac-YVAD-CMK together with Z-DEVD-FMK; 50 and 100 µM) or with NGF (6 nM). At the beginning of the incubation as well as 24 and 48 h later, the cells were collected and assayed for internucleosomal degradation of DNA by the Cell Death Detection Elisa Plus kit. The results (means ± S.D. of three different experiments run in triplicate) are expressed as arbitrary units (absorbance at 405 nm/µg of protein).

The dependence of ceramide levels and caspase activity on p75NTR was further investigated in the transfected clones by treatment with a natural ligand of the receptor, NGF. For both parameters, this neurotrophin (6 nM) induced significant decreases, which, however, required long periods (tenths of hours) to develop (see Fig. 3 for clone B). Since the employed cells express neither TrkA nor any other Trk receptor, as revealed by Western blots (Fig. 4B) (20), the protective effect of NGF can only be attributed to the expressed p75NTR.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of NGF treatment on ceramide levels (A) and caspase activity (B) in p75NTR-overexpressing clone B. Clone B cells were incubated for the indicated time periods in cell culture medium supplemented with 6 nM NGF. At the beginning of the incubation as well as 24 and 48 h later, the cells were collected, washed, and processed for either ceramide assay (A) or caspase activity (B). The results (means ± S.D. of five experiments run in duplicate) are expressed as described in the legend to Fig. 2. In A, the bottom of the columns are the values in wild-type cells.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 4.   Characterization of the p75NTR-overexpressing clone resistant to spontaneous and exogenous ceramide-induced apoptosis (AR clone). A, Western blot analysis of p75NTR expression in wild-type cells and p75NTR-expressing clones carried out using an antibody specific for the transfected receptor (lane a, wild-type cells; lane b, clone B; lane c, clone H; lane d, clone Hy-; lane e, clone AR). The two bars on the left indicate the positions of the two forms (glycosylated and non-glycosylated) of p75NTR (75 and 59 kDa). Thirty µg of protein were loaded on each lane. The results shown are representative of three to five separate experiments. B, Western blot analysis carried out with an antibody that recognizes all the Trk receptors (lane a, PC12 cells, employed as a positive control; lane b, wild-type SK-N-BE cells; lane c, AR clone). The two bars on the left indicate the positions of Trk receptor isoforms in PC12 cells (140 and 110 kDa). The results shown are representative of three to four separate experiments. C, FACS analysis of the DNA in clone AR cells while under resting conditions (left panel) and after overnight treatment with either ceramide (50 µM; middle panel) or ionomycin (5 µM; right panel). Representation is as described for Fig. 1A. Notice that the apoptotic cell peak is appreciable only in ionomycin-treated cells (arrowhead). The results shown are representative of three experiments. D, effect of pretreatment with NGF (6 nM) added for the indicated times on ceramide levels in clone AR. The values in clone B (see Fig. 2A) are also reported for reference. The results are means ± S.D. of two experiments run in duplicate.

An Apoptosis-resistant p75NTR-transfected Clone-- A new clone transfected with the p75NTR cDNA (BEp75AR, indicated below as clone AR) differs profoundly from those described so far (20). The level of p75NTR expression was high in clone AR, comparable to that in clones B and H (Fig. 4A), and Trk receptors were not detectable (Fig. 4B). Yet the AR clone tendency to apoptosis was low, not only under resting conditions, but also after ceramide administration (Fig. 4C, left and middle panels). In contrast, clone AR was as susceptible as the other clones to treatments known to induce apoptosis by non-receptor mechanisms, such as exposure to the Ca2+ ionophore ionomycin (5 µM) (Fig. 4C, right panel; and data not shown). In terms of endogenous ceramide, clone AR resembled the p75NTR-overexpressing clones, B and H, with high resting levels (~11.5 µM), which decreased with time following exposure to NGF (Fig. 4D).

A number of mechanisms that could account for the resistance to apoptosis of the AR clone were investigated. The levels of the apoptosis controller oncogene product, Bcl-2, and of caspases were similar to those found in the other clones (Western blotting) (data not shown). Yet when caspase activity was assayed by the use of a fluorescent substrate, clone AR exhibited very low levels, thus resembling not the other p75NTR-overexpressing clones, but the wild-type parental cells (Fig. 5). Moreover, the caspase activity remained unchanged when clone AR was exposed to exogenous ceramide, a treatment that, even in wild-type cells, induces large increases, exceeding with time the levels observed in the unstimulated p75NTR-overexpressing clones (Fig. 5). From these data, we conclude that, in the AR clone, the tendency to apoptosis induced by p75NTR overexpression is balanced specifically by one (or more) additional event(s) by which the death signaling cascade is blocked upstream of caspase activation.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   Caspase activity assayed under resting conditions and upon exogenous ceramide application in wild-type SK-N-BE cells and in the various p75NTR-overexpressing clones. Total cell lysates obtained from either the wild-type (wt) cells or the various p75NTR-transfected SK-N-BE clones, under resting conditions or after exogenous ceramide (50 µM) administration for different times (0, 2, 4, 6, and 16 h), were mixed at 37 °C with a 50 µM concentration of the fluorogenic substrate Ac-DEVD-AMC, and the fluorescence increase following the cleavage of the AMC residue was monitored for 10 min in a spectrofluorometer. The results (means ± S.D.) are from three separate experiments run in duplicate.

Role of NO-- A series of experiments was carried out to explore the possibility that NO has a role in the regulation of apoptosis in SK-N-BE clones. NO synthase activity was found to vary profoundly in the various clones. Compared with controls, it was clearly increased in the resistant AR clone and greatly reduced in the sensitive clones, especially clones H and B (Fig. 6). In general terms, therefore, this variability correlates inversely to the sensitivity to exogenous ceramide. Exposure to the blocker L-NAME induced large drops in the NO synthase activity, which were parallel in all the preparations investigated (Fig. 6).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 6.   NO synthase activity in wild-type SK-N-BE cells and in the various p75NTR-expressing clones. NO synthase (NOS) activity was assayed in the total homogenates of wild-type (wt) SK-N-BE cells and of the various p75NTR-overexpressing clones, prepared both under resting conditions and in the presence of the NO synthase inhibitor L-NAME (500 µM), employed as an internal control. The results shown (means ± S.D.) are from three separate experiments run in triplicate.

Additional evidence for a role of NO was obtained by experiments in which spontaneous apoptosis was significantly reduced in the p75NTR-overexpressing B and H clones by pretreatment with the NO donor SNAP as revealed by various tests, including fluorescein isothiocyanate-annexin V staining and nucleosome accumulation (Table II). The same donor, administered to wild-type cells, was able to prevent (in a dose-dependent fashion) the apoptosis induced by exogenous ceramide (50 µM) (Fig. 7A) and to inhibit the activity of caspases (Fig. 7B). Such a protection was due to NO generation from the donor, and not to other effects of the compound, because it faded out completely when the messenger was trapped by addition of hemoglobin (100 µM) to the cell incubation mixture (Fig. 7A). Likewise, the high caspase resting levels were reduced in the p75NTR-overexpressing cells by the NO donor (Fig. 7C), which, in contrast, failed to modify the high levels of endogenous ceramide (data not shown). As far as the mechanisms by which the protective effects of NO are induced, experiments were carried out in which both wild-type and clone B cells were treated with the membrane-permeable cGMP analogue 8-Br-cGMP (0.5 mM) before exogenous ceramide administration or under resting conditions. Since this treatment did not affect the caspase activity (Fig. 7, B and C) or apoptosis (data not shown), we conclude that one of the classical mediators of NO action, the activation of guanylate cyclase, is most likely not involved in its anti-apoptotic effect.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Protective effect of the NO donor SNAP against apoptosis in the p75NTR-overexpressing clones as revealed by two independent procedures
The wild-type SK-N-BE cells and the two p75NTR-overexpressing B and H clone cells were incubated for 48 h in culture medium supplemented with SNAP (300 µM), harvested, and then assayed for apoptosis quantified by both annexin V staining (upper panel) and the Cell Death Detection Elisa Plus kit (lower panel) as described under "Experimental Procedures." The results (means ± S.D. of three different experiments run in triplicate) are expressed as percentages of cells stained by fluorescein isothiocyanate annexin V and arbitrary absorbance units/µg of protein, respectively. The increase of apoptotic cells in the wild-type preparations is interpreted as an unspecific toxic effect of the NO donor.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 7.   Inhibition by the NO donor SNAP of both apoptosis (A) and caspase activity (B and C) in wild-type SK-N-BE (A and B) and clone B (C) cells. A, wild-type SK-N-BE cells were preincubated for 15 min without (panels a and b) or with (panels c and d) the NO donor SNAP (300 µM) in the presence (panel d) or absence (panel c) of the NO scavenger hemoglobin, (100 µM) before receiving, in addition, exogenous ceramide (50 µM overnight) (panels b-d). Apoptotic cells were revealed by DNA FACS analysis as specified in the legend to Fig. 1A. The results are representative of two consistent experiments. B, wild-type SK-N-BE cells were preincubated for 15 min either with the indicated concentrations of SNAP or with the membrane-permeable cGMP analogue 8-Br-cGMP before receiving, in addition, exogenous ceramide (50 µM, 4 h). C, clone B cells were preincubated for 48 h (changes every 12 h) with either SNAP or 8-Br cGMP at the indicated concentrations before assaying the caspase activity. In both B and C, caspase activity measurements were performed on total cell homogenates by monitoring the cleavage of the fluorogenic substrate Ac-DEVD-AMC. Values are shown as described in the legends to Figs. 2B and 5. The results (means ± S.D.) are from three separate experiments run in duplicate.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Interest about p75NTR has been greatly stimulated by the conflicting results reported about its function. In cells in which its expression occurs together with that of the other NGF receptor, the tyrosine kinase TrkA, p75NTR has been shown to contribute to the trophic effects induced by ligand binding, playing either a tuning (4, 5, 28, 29) or a true synergistic (30) role. Recently, however, p75NTR has been recognized as a death receptor, belonging to the same molecular family as the tumor necrosis factor-alpha receptor and CD95, and ample evidence of p75NTR-induced apoptosis has been reported (10, 11). Whether the latter effect is induced by the receptor when free or after binding of one of its ligands, such as NGF, remains debated. In two studies in which the binding mode was reported (in oligodendrocytes (Ref. 12; however, see also Ref. 31) and in chick retina neurons (Ref. 13)), the pro-apoptotic activation of p75NTR was shown to trigger the generation of ceramide. This finding is of importance because the lipid derivative, no matter whether generated endogenously or administered exogenously, is known to play a key role in the induction of apoptosis (32, 33). On the other hand, spontaneous apoptosis taking place in p75NTR-expressing cells in the absence of NGF was demonstrated in immortalized neural cells and sensory neurons (34, 35) as well as in the overexpressing SK-N-BE clones employed in this study (20). The intracellular signaling events operative in these various cases were not investigated.

To reconcile these results, a detailed understanding of the p75NTR transduction system would be needed. Activation of other death receptors, such as the tumor necrosis factor-alpha receptor, is known to trigger not a single, but a number of intracellular cascades, only some of which lead to apoptosis, whereas others ultimately induce cell protection and/or proliferation (32, 36, 37). The equilibrium among these various pathways appears to be regulated in a cell type-specific fashion. A task of this work was to elucidate the mechanisms by which p75NTR triggers and regulates its spontaneous apoptotic response in SK-N-BE cells. The results we have obtained emphasize the role of both ceramide and caspases. The high levels of endogenous ceramide observed in the p75NTR-overexpressing cells were shown to decline, although slowly (24-48 h), after administration of NGF, in parallel with the strong decrease in the probability of apoptosis (20). The possibility that high ceramide levels increase the probability of cells to enter the apoptotic program is confirmed also by their higher sensitivity to the exogenous lipid metabolite. Our ceramide results with NGF are just the opposite of what was reported for oligodendrocytes (12), suggesting that the p75NTR transmembrane signaling can vary, depending on the cell type, and thus explaining the apparently contradictory results of the literature. In the case of caspases, the enzymes known to play key operative roles in the cell death program, our present evidence strongly suggests their involvement in the p75NTR signaling (7, 8). In the p75NTR-overexpressing B and H clones, the caspase activity was found to be very high already under resting conditions. Exposure to exogenous ceramide induced increases not only in the overexpressing cells, but also in the wild-type cells, correlating with the development of apoptosis. Along the same line, a negative correlation was found between apoptosis and the effects of caspase inhibitors.

New and profoundly different results were obtained with clone AR, the p75NTR-overexpressing SK-N-BE clone that diverges from the others because of its resistance to apoptosis. Resting clone AR cells are characterized by high ceramide levels and by caspase expression levels comparable to those of the other clones. The signaling difference of clone AR emerged when its low caspase activity failed to rise and its cells failed to enter apoptosis when exposed to exogenous ceramide. Apparently, therefore, the resistance of clone AR is due to a transduction blockade localized between p75NTR signaling and ceramide generation on the one hand and caspase activation on the other. Such a blockade appears specific for the receptor-initiated pathway since, when other inducing treatments were employed, no difference in apoptosis development was observed between clone AR and the other clones. Of the cell properties that could be possibly responsible for clone AR resistance, some (expression of Trk receptors and increased levels of Bcl-2) could be excluded. A difference detected in clone AR with respect to the other overexpressing clones and also the wild-type SK-N-BE cells was, in contrast, its high NO synthase activity. Thus, NO could have a part in the lack of caspase activation and apoptosis in clone AR cells; whether other, so far unidentified protective factor(s) are also involved remains to be established.

In previous studies, the conclusions about the role of NO in nerve cell apoptosis had been conflicting. In many cases, the messenger was reported to induce (38-40) and in others to protect from (41, 42) programmed cell death. In our work, the protective role of NO was documented by (i) the inverse correlation between NO synthase activity and apoptosis (both spontaneous and induced by ceramide) and (ii) the effects of an NO donor (SNAP) that was able to prevent the ceramide activation of caspases and induced marked decreases in programmed death rates in both the wild-type cells and p75NTR-overexpressing B and H clones. The latter effects were specific because they disappeared when the cells were incubated in the presence of the NO scavenger hemoglobin. Thus, endogenous NO appears to be among the controllers modulating the efficacy of the p75NTR-triggered death signal. This finding is of importance for at least two reasons. (i) It shows that the protective role of endogenously generated NO against receptor-triggered apoptosis is not confined to individual receptors and cell types (CD95 in T lymphocytes (16, 17) and the tumor necrosis factor-alpha receptor in endothelial cells (19)), but extends to p75NTR in a nerve cell; and (ii) it provides clues about the role of NO in the development and plasticity of the nervous system (see, for example, Ref. 37). Evidence for the involvement of the gaseous messenger in such processes was already available for the visual (43, 44) and olfactory (45) systems as well as for peripheral sensory neurons (35, 46); however, the mechanisms involved remained unclear. Based on the present results, it is conceivable that at least part of the NO effects, in the above and possibly also in other parts of the nervous system, are established via its involvement in the regulation of death signaling programs, such as that activated by p75NTR.

In conclusion, the panel of stably transfected SK-N-BE neuroblastoma clones lacking Trk have shown to be interesting models for the study of the signaling and physiological role of the p75NTR receptor. The higher efficacy of the latter in inducing apoptosis in the absence rather than in the presence of its ligand might account for the neurotrophic role attributed in previous studies (30) to the NGF activation of p75NTR working synergistically with TrkA. In other cell types, however, classical apoptotic responses have been triggered following ligand activation of p75NTR (12, 13), as expected for a bona fide death receptor. These apparently conflicting results call attention to the mechanisms that regulate intracellularly the development of the apoptotic program. In this study on p75NTR-expressing SK-N-BE clones, the event that seems to play a major role is the generation of NO. In fact, high levels of the gaseous messenger inhibit the activation of caspases by a mechanism that appears to be cGMP-independent. Therefore, in the case of p75NTR-induced apoptosis, at least two levels of control appear to be functioning: at the receptor, with its alternative free/bound signaling; and within the cytoplasm, where multiple signals, including those triggered by NO, appear to participate in the regulation of the life-or-death decision (11).

    FOOTNOTES

* This work was supported in part by grants from the Italian Association for Cancer Research; Special Project Apoptosis, University of Bologna; the Co-funding Program of the Italian Ministry of University and Research; the Armenise-Harvard Foundation; and Target Project Biotechnology, Consiglio Nazionale delle Ricerche. The support of Italian Schering Plough is gratefully acknowledged.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These two authors contributed equally to this work.

Supported by a fellowship from INSERM.

§§ To whom correspondence should be addressed: DIBIT, Dept. of Neuroscience, San Raffaele Inst., Via Olgettina, 58, 20132 Milan, Italy. Tel.: 2-2643-2770; Fax: 2-2643-4813; E-mail: meldolesi.jacopo{at}hsr.it.

    ABBREVIATIONS

The abbreviations used are: NGF, nerve growth factor; NTR, neurotrophin receptor; NO, nitric oxide; AMC, 7-amino-4-methylcoumarin; CMK, chloromethyl ketone; FMK, fluoromethyl ketone; Z-, benzyloxycarbonyl-; SNAP, S-nitrosoacetylpenicillamine; L-NAME, L-Nomega -nitro-L-arginine methyl ester; PBS, phosphate-buffered saline; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; FACS, fluorescence-activated cell sorter.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Raff, M. C., Barres, B. A., Burne, J. F., Coles, H. S., Ishizaki, Y., and Jacobson, M. D. (1993) Science 262, 695-700[Medline] [Order article via Infotrieve]
  2. Henderson, Z. (1996) Prog. Neurobiol. (Oxf.) 48, 219-254[CrossRef][Medline] [Order article via Infotrieve]
  3. Stefanis, L., Burke, R. E., and Greene, L. A. (1997) Curr. Opin. Neurobiol. 10, 299-305
  4. Heumann, R. (1994) Curr. Biol. 4, 668-679
  5. Chao, M. V., and Hempstead, B. L. (1995) Trends Neurosci. 18, 321-326[CrossRef][Medline] [Order article via Infotrieve]
  6. Greene, L. A., and Kaplan, D. R. (1995) Curr. Biol. 5, 579-587
  7. Nagata, S. (1997) Cell 88, 355-365[Medline] [Order article via Infotrieve]
  8. Salvesen, G. S., and Dixit, V. M. (1997) Cell 91, 443-446[Medline] [Order article via Infotrieve]
  9. Bredesen, D. E., and Rabizadeh, S. (1997) Trends Neurosci. 20, 287-290[CrossRef][Medline] [Order article via Infotrieve]
  10. Majdan, M., Lachance, C., Gloster, A., Aloyz, R., Zeindler, C., Bamji, S., Bhakar, A., Belliveau, D., Fawcett, J., Miller, F. D., and Barker, P. A. (1997) J. Neurosci. 17, 6988-6998[Abstract/Free Full Text]
  11. Miller, F. D., and Kaplan, D. R. (1998) Cell Death Differ. 5, 343-345[CrossRef][Medline] [Order article via Infotrieve]
  12. Casaccia-Bonnefil, P., Carter, B. D., Dobrowsky, R. T., and Chao, M. V. (1996) Nature 383, 716-719[CrossRef][Medline] [Order article via Infotrieve]
  13. Frade, J. M., Rodriguez-Tébar, A., and Barde, Y.-A. (1996) Nature 383, 166-168[CrossRef][Medline] [Order article via Infotrieve]
  14. Aloyz, R. S., Bamji, S. X., Pozniak, C. D., Toma, J. G., Atwal, J., Kaplan, D. R., and Miller, F. D. (1998) J. Cell Biol. 143, 1691-1703[Abstract/Free Full Text]
  15. Nicotera, P., Brune, B., and Bagetta, G. (1997) Trends Pharmacol. Sci. 18, 189-190[CrossRef][Medline] [Order article via Infotrieve]
  16. Sciorati, C., Rovere, P., Ferrarini, M., Heltai, S., Manfredi, A. A., and Clementi, E. (1997) J. Biol. Chem. 272, 23211-23215[Abstract/Free Full Text]
  17. Hebestreit, H., Dibbert, B., Balatti, I., Braun, D., Schapowal, A., Blaser, K., and Simon, H. U. (1998) J. Exp. Med. 187, 415-425[Abstract/Free Full Text]
  18. Mannick, J. B., Miao, X. Q., and Stamler, J. S. (1997) J. Biol. Chem. 272, 24125-24128[Abstract/Free Full Text]
  19. Dimmeler, S., Haendeler, J., Nehls, M., and Zeiher, A. M. (1997) J. Exp. Med. 4, 601-607
  20. Bunone, G., Mariotti, A., Compagni, A., Morandi, E., and Della Valle, G. (1997) Oncogene 14, 1463-1470[CrossRef][Medline] [Order article via Infotrieve]
  21. Ferrarini, M., Heltai, S., Toninelli, E., Sabbadini, M. G., Pellicciari, C., and Manfredi, A. A. (1995) J. Immunol. 154, 3704-3712[Abstract/Free Full Text]
  22. Martin, S. J., Reutelingsperger, C. P. M., McGahon, A. J., Rader, J. A., van Schie, R. C. A. A., LaFace, D. M., and Green, D. R. (1995) J. Exp. Med. 182, 1545-1556[Abstract]
  23. Rooney, E., and Meldolesi, J. (1996) J. Biol. Chem. 271, 29304-29311[Abstract/Free Full Text]
  24. Bredt, D. S., and Snyder, S. H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 682-685[Abstract]
  25. Srinivasan, A., Foster, L. M., Testa, M. P., Ord, T., Keane, R. W., Bredesen, D. E., and Kayalar, C. (1996) J. Neurosci. 16, 5654-5660[Abstract/Free Full Text]
  26. Farschon, D. M., Couture, C., Mustelin, T., and Newmeyer, D. D. (1997) J. Cell Biol. 137, 1117-1125[Abstract/Free Full Text]
  27. Schwandner, R., Wiegmann, K., Bernardo, K., Kreder, D., and Kronke, M. (1998) J. Biol. Chem. 273, 5916-5922[Abstract/Free Full Text]
  28. Verdi, J. M., Birren, S. J., Ibanez, C. F., Persson, H., Kaplan, D. R., Benedetti, M., Chao, M. V., and Anderson, D. J. (1994) Neuron 12, 733-745[Medline] [Order article via Infotrieve]
  29. MacPhee, I. J., and Barkers, P. A. (1997) J. Biol. Chem. 272, 23547-23551[Abstract/Free Full Text]
  30. Maliartchouk, S., and Saragovi, H. U. (1997) J. Neurosci. 17, 6031-6037[Abstract/Free Full Text]
  31. Ladiwala, U., Lachance, C., Simoneau, S. J. J., Bhakar, A., Barker, P. A., and Antel, J. P. (1998) J. Neurosci. 18, 1297-1304[Abstract/Free Full Text]
  32. Wiegmann, K., Schutze, S., Macleidt, T., Witte, D., and Kronke, M. (1994) Cell 78, 1005-1015[Medline] [Order article via Infotrieve]
  33. Cifone, M., Roncaioli, P., De Maria, R., Camarda, G., Santoni, A., Ruberti, G., and Testi, R. (1995) EMBO J. 14, 5859-5868[Abstract]
  34. Rabizadeh, S., Oh, J., Zhong, L., Yang, J., Bitler, C. M., Butcher, L. L., and Bredesen, D. E. (1993) Science 261, 345-348[Medline] [Order article via Infotrieve]
  35. Barrett, G. L., and Bartlett, P. F. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6501-6505[Abstract]
  36. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S. (1998) Science 281, 1680-1683[Abstract/Free Full Text]
  37. Hehner, S. P., Hofmann, T. G., Ratter, F., Dumont, A., Droge, W., and Schmitz, M. L. (1998) J. Biol. Chem. 273, 18117-18121[Abstract/Free Full Text]
  38. Zhang, J., and Snyder, S. H. (1995) Annu. Rev. Pharmacol. Toxicol. 35, 213-233[CrossRef][Medline] [Order article via Infotrieve]
  39. Yun, H. Y., Dawson, V. L., and Dawson, T. M. (1996) Crit. Rev. Neurobiol. 10, 291-316[Medline] [Order article via Infotrieve]
  40. Samdani, A. F., Newcamp, C., Resink, A., Facchinetti, F., Hoffman, B. E., Dawson, V. L., and Dawson, T. M. (1997) J. Neurosci. 17, 4633-4641[Abstract/Free Full Text]
  41. Lipton, S. A., Choi, Y. B., Pan, Z. H., Lei, S. Z., Chen, H. S., Sucher, N. J., Loscalzo, J., Singel, D. J., and Stamler, J. S. (1993) Nature 364, 577-587[Medline] [Order article via Infotrieve]
  42. Tenneti, L., Demilia, D. M., and Lipton, S. A. (1997) Neurosci. Lett. 236, 139-142[CrossRef][Medline] [Order article via Infotrieve]
  43. Williams, C. V., Nordquist, D., and McLoon, S. C. (1994) J. Neurosci. 14, 1746-1755[Abstract]
  44. Wu, H. H., Williams, C. V., and McLoon, S. C. (1994) Science 265, 1593-1596[Medline] [Order article via Infotrieve]
  45. Roskams, A. J., Bredt, D. S., Dawson, T. M., and Ronnett, G. V. (1994) Neuron 13, 289-299[Medline] [Order article via Infotrieve]
  46. Lee, K. F., Li, E., Huber, J., Landis, S. C., Sharpe, A. H., Chao, M. V., and Jaenisch, R. (1992) Cell 69, 737-749[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.